Form 483 Flicker: Piramal Pharma’s Lexington Facility Gets a Regulatory Nudge

Piramal Pharma Limited has disclosed that the US Food and Drug Administration conducted a General Good Manufacturing Practices inspection at its Lexington, Kentucky facility between December 3 and December 10, 2025. At the conclusion of the inspection, the agency issued a Form 483 with four observations. These observations are related to procedural enhancements and have been classified as Voluntary Action Indicated, indicating that no immediate regulatory action is required. The company is preparing a comprehensive response to the FDA, which will be submitted within the stipulated timelines. Piramal Pharma reaffirmed its commitment to maintaining the highest standards of compliance and will work closely with the FDA to address all observations.

 

Notable Updates

Major Takeaways

Important Points

Source: NSE Corporate Announcement, Piramal Pharma Limited official announcement, Reuters, Marketscreener